Clinical Trials Logo

Pancreatic Cancer clinical trials

View clinical trials related to Pancreatic Cancer.

Filter by:

NCT ID: NCT03205176 Completed - Breast Cancer Clinical Trials

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

Start date: June 30, 2017
Phase: Phase 1
Study type: Interventional

This is a first-time-in-man (FTIM) multicenter, dose escalation study designed to investigate the safety, pharmacokinetics, and pharmacodynamics of AZD5153 in patients with malignant solid tumors, including lymphomas.

NCT ID: NCT03200821 Completed - Pancreatic Cancer Clinical Trials

An Open Label Study to Evaluate G17DT Compared to Gemcitabine

Start date: August 14, 2000
Phase: Phase 3
Study type: Interventional

In this study 250 µg of G17DT was administered at Weeks 0, 2 and 6 in order to demonstrate non inferiority compared to gemcitabine in prolonging survival in advanced pancreatic cancer.

NCT ID: NCT03190265 Completed - Pancreatic Cancer Clinical Trials

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Start date: December 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to study the safety and clinical activity of nivolumab and ipilimumab in combination with either sequential administration of CY/GVAX pancreas vaccine followed by CRS-207 (Arm A) or with administration of CRS-207 alone (Arm B) in patients with pancreatic cancer.

NCT ID: NCT03187028 Completed - Pancreatic Cancer Clinical Trials

Diet and Exercise After Pancreatic Cancer

PACE
Start date: August 3, 2017
Phase: N/A
Study type: Interventional

Determine feasibility of a randomized controlled trial (RCT) in pancreatic (& other foregut) cancer patients comparing the effects of diet alone vs. diet+exercise on functional and clinical outcomes.

NCT ID: NCT03184870 Completed - Colorectal Cancer Clinical Trials

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Start date: August 8, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug effects, and preliminary efficacy of BMS-813160 alone or in combination with either chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic colorectal and pancreatic cancers.

NCT ID: NCT03180437 Completed - Pancreatic Cancer Clinical Trials

Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer

Start date: June 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

In this study, effects of γδT cells on human Pancreatic Cancer in combination with tumor reducing surgery, for example IRE going to be investigated.

NCT ID: NCT03161379 Completed - Pancreatic Cancer Clinical Trials

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Start date: February 2, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and clinical activity of FOLFIRINOX along with a whole cell vaccine with immune modulating doses of cyclophosphamide and nivolumab combined with Stereotactic Body Radiation Therapy (SBRT) in patients with pancreatic cancer.

NCT ID: NCT03158779 Completed - Pancreatic Cancer Clinical Trials

Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer

Start date: May 10, 2017
Phase: Phase 2
Study type: Interventional

The aim of this phase II study is to assess the efficacy and safety of sequentially integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and SBRT in patients with unresectable pancreatic cancer.

NCT ID: NCT03153410 Completed - Pancreatic Cancer Clinical Trials

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Start date: September 27, 2018
Phase: Early Phase 1
Study type: Interventional

This study will be looking at whether combining cyclophosphamide, pembrolizumab (an antibody that blocks negative signals to T cells), GVAX (pancreatic cancer vaccine), and IMC-CS4 (LY3022855) (an antibody that blocks a molecule called CSF1-R which prevents the bodies ability to fight cancer) is effective (anti-tumor activity) and safe in patients with borderline resectable pancreatic cancer.

NCT ID: NCT03152487 Completed - Pancreatic Cancer Clinical Trials

Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis

Start date: April 24, 2017
Phase: N/A
Study type: Interventional

Pancreatic cancer is the second most common gastrointestinal malignancy. Abdominal discomfort is a main symptom in patients with pancreatic cancer. Approximately 75% have pain at diagnosis and over 90% in advanced stages. Pain control is an important part of the plan of care for patients with pancreatic cancer.. The celiac plexus is a group of nerves that supply organs in the abdomen. EUS-guided celiac plexus neurolysis (EUS-CPN) has been widely used for pain management in patients with pancreatic cancer. Radiofrequency ablation of celiac ganglia or celiac plexus (EUS-RFA) is also being performed to alleviate abdominal pain in pancreatic cancer patients. However currently no comparative studies exist comparing EUS-CPN with EUS-RFA. The purpose of the study is to compare EUS-CPN with EUS-RFA for pain management in pancreatic patients, in order to determine which technique is better at improving pain in pancreatic cancer patients.